Get 40% Off
These stocks are up over 10% post earnings. Did you spot the buying opportunity? Our AI did.Read how

6 Stock Charts To Watch: ABUS, ADAP, FLGT, PBYI, RVNC, SELB

Published 02/06/2020, 02:56 AM
Updated 07/09/2023, 06:31 AM

1. Arbutus Biopharma Corporation (ABUS)

Arbutus Biopharma (NASDAQ:ABUS) has had a fantastic run since Oct, going from under a dollar, all the way up to 3 3/4, it consolidated in a 3-wave, corrective pullback flag, and on Wednesday, it popped with a breakaway gap, up 43 cents, or 15.3%, to 3.24, six points off the 3.30 session high, on 1.6 million shares traded. That’s the biggest volume in about two months. Now, let’s see if it will retest 3 3/4, and then 4 1/4. I think the swing targets are 5 1/2 and 6 3/4

2. Adaptimmune Therapeutics plc (ADAP)

Adaptimmune Therapeutics (NASDAQ:ADAP) is a swing trade of ours that we are watching very carefully. It broke out of a coil on Wednesday and ran 46 cents, or 11.39%, to 4.50, after reaching a high of 4.65, on 1.7 million shares traded. The volume increased a little bit but not enough. If it gets through 4.80-.85, then we’re looking at 6 1/4.

3. Fulgent Genetics, Inc. (FLGT)

Fulgent Genetics (NASDAQ:FLGT) also broke out of a coil on Wednesday, and jumped 1.52, or 11%, to 15.42, not far off the session high at 15.50, on 458,587 shares traded. That’s the biggest volume in about two months. It’s awfully solid here, and if it can get through this zone, and then take out 16 1/2, that’s my target. Mid-channel target is around 18 1/2-19.

4. Puma Biotechnology, Inc. (PBYI)

Puma Biotechnology (NASDAQ:PBYI) exploded Wednesday, jumping 3.98 or 38%, to 14.56, after reaching a high of 15.00, on a whopping 23 million shares traded. I’m looking for a test now of about the 17 3/4-18 range, and then we’ll look at 20 going forward.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

5. Revance Therapeutics, Inc. (RVNC)

The Revance (NASDAQ:RVNC) broke out of a wedge as well on Wednesday at the top of the channel, gaining another 1.53, or 6.5%, to 25.07, just two cents off the session and 52-week high at 25.09, on 615,691 shares traded. If it accelerates here, I would be looking at 27 next. With resistance overhead, it may see 30.

6. Selecta Biosciences, Inc. (SELB)

Selecta Biosciences (NASDAQ:SELB) popped 76 cents, or 20.8%, to 4.41, after reaching the session and 52-week high of 4.79, on 1.5 million shares traded on Wednesday. On the daily chart, it looks like it may extend to the 6 1/4 range.

Stocks on the long side

Arbutus Biopharma Corporation (ABUS), Adaptimmune Therapeutics plc (ADAP), Anavex Life Sciences Corp. (AVXL), BioXcel Therapeutics, Inc. (BTAI), Clovis Oncology, Inc. (CLVS), Cyclerion Therapeutics, Inc. (CYCN), 3D Systems Corporation (DDD), Fulgent Genetics, Inc. (FLGT), Grayscale Bitcoin Trust (BTC) (GBTC), MasterCraft Boat Holdings, Inc. (MCFT), Mallinckrodt plc (NYSE:MNK), Nautilus, Inc. (NLS), O-I Glass, Inc. (OI), Puma Biotechnology, Inc. (PBYI), Revance Therapeutics, Inc. (RVNC), SmileDirectClub, Inc. (SDC), and Selecta Biosciences, Inc. (SELB).

Watch video here...

Latest comments

great analysis look forward to next week
thanks harry
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.